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Abstract
Introduction TNFα and high mobility group box chromosomal
protein 1 (HMGB1) are two potent proinflammatory cytokines
implicated as important mediators of arthritis. Increased levels of
these cytokines are found in the joints of rheumatoid arthritis
patients, and the cytokines trigger arthritis when applied into the
joints of naïve mice. HMGB1 is actively released from immune
cells in response to TNFα; once released, HMGB1 in turn
induces production of several proinflammatory cytokines –
including IL-6 and TNFα – by macrophages. Whether HMGB1-
induced arthritis is mediated via the TNFα pathway, however, is
unknown. The purpose of the present study was to investigate
whether the arthritis-inducing effect of HMGB1 is dependent on
TNFα expression in vivo and to assess whether TNFα
deficiency affects a proinflammatory cytokine response to
HMGB1 in vitro.
Methods TNFα knockout mice and backcrossed control
animals on a C57Bl6 background were injected intraarticularly
with 5 μg HMGB1. Joints were dissected 3 days after
intraarticular injection and were evaluated histologically by
scoring the frequency and severity of arthritis. For in vitro
studies, mouse spleen cultures from TNFα knockout mice and
from control mice were incubated with different doses of
HMGB1, and cell culture supernatants were collected at
different time points for analysis of IL-6.
Results Intraarticular injection of HMGB1 into healthy mouse
joints resulted in an overall frequency of 32% to 39% arthritic
animals. No significant differences were found with respect to
the severity and incidence of synovitis between mice deficient
for TNFα (seven out of 18 mice with arthritis) in comparison with
control TNFα+/+  animals (six out of 19). No significant
differences were detected between spleen cells from TNFα+/+
mice versus TNFα-/-  mice regarding IL-6 production upon
stimulation with highly purified HMGB1 after 24 hours and 48
hours. Upon stimulation with a suboptimal dose of recombinant
HMGB1, however, the splenocytes from TNFα+/+  animals
released significantly more IL-6 than cells from the knockout
mice (602 ± 112 pg/ml and 304 ± 50 pg/ml, respectively; P <
0.05).
Conclusion Our data show that HMGB1-triggered joint
inflammation is not mediated via the TNF pathway. Combined
with our previous study, we suggest that HMGB1-triggered
arthritis is probably mediated through IL-1 activation.
Introduction
Rheumatoid arthritis is an autoimmune disease characterized
by chronic inflammation in the joints leading to destruction of
articular cartilage and bone. The pathogenesis of the disease
is complex, involving a wide range of cytokines and endog-
enous proinflammatory molecules.
High mobility group box chromosomal protein 1 (HMGB1), a
nuclear DNA-binding protein, proved recently to be a potent
proinflammatory cytokine implicated as an important mediator
of arthritis [1]. Increased levels of HMGB1 are found in the
joints of rheumatoid arthritis patients [2,3], and the protein trig-
gers arthritis when applied into the joints of naïve mice [4].
HMGB1 is actively released from immune cells in response to
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different stimuli, including TNFα and lipopolysaccharide
(LPS). Previous studies have reported that IFN-γ plays an
important role in the regulation of HMGB1 release partly
through a TNFα-dependent mechanism [5]. Chen and col-
leagues demonstrated that direct suppression of TNF activity
with neutralizing antibodies or genetic disruption of TNF
expression partially attenuated LPS-induced HMGB1 release
from macrophages [6]. Once released, HMGB1 generates a
positive feedback loop and in turn induces production of sev-
eral proinflammatory cytokines – such as IL-6, IL-1β and TNFα
– by macrophages, thereby sustaining prolonged inflammation
[7].
To what extent the ability of HMGB1 to induce arthritis is medi-
ated via the TNFα pathway and whether the presence of TNFα
gene affects the proinflammatory cytokine production in
response to HMGB1, however, are unknown. In the present
study we examined whether the HMGB1-induced joint inflam-
mation is dependent on TNFα signalling.
Materials and methods
Mice
Female and male TNFα knockout mice and backcrossed con-
trol animals on a C57Bl6 background were bred at the Insti-
tute of Immunology, Biomedical Sciences Research Center
'Al. Fleming', Greece. The animals were housed in the animal
facility of the Department of Rheumatology and Inflammation
Research, University of Göteborg, Sweden. The mice were
kept under standard conditions of temperature and light, and
were fed laboratory chow and water ad libitum. The study was
approved by the Ethical Committee of Göteborg University,
and the requisitions of the National Board for Laboratory Ani-
mals were followed.
Reagents
Mouse recombinant HMGB1 (rHMGB1) was expressed in
Escherichia coli and purified to homogeneity as previously
described [8]. Preparations were tested for LPS content by
the chromogenic Limulus amebocyte lysate assay and con-
tained <2 ng endotoxin/μg rHMGB1. Highly purified recom-
binant endotoxin-free HMGB1 (pHMGB1) (purchased from
HMGBiotech, Milano, Italy) was also used for experiments.
LPS from E. coli serotype 055:B5 was purchased from Sigma
(Saint Louis, MO, USA).
Injection protocol
In the first experiment, TNFα-/- mice and backcrossed control
animals on a C57Bl6 background were injected intraarticularly
with 5 μg pHMGB1. In the second experiment, mice received
the intraarticular injection of 5 μg rHMGB1 and the contralat-
eral knee was injected with 10 ng LPS, which corresponded
to the amount of LPS found in rHMGB1 preparations.
Histologic examination
Three days after the intraarticular injections, the optimal time
to trigger synovitis [4], the mice were sacrificed. The knee
joints were removed, fixed in 4% formaldehyde, decalcified,
embedded in paraffin, sectioned and stained with H&E. All of
the slides were assessed in a blinded manner by two research-
ers (RP and AT). The extent of synovitis was judged on an arbi-
trary scale from grade 0 to grade 3, as described elsewhere
[4].
In vitro experiments
Spleen cells from TNFα-/- mice and from control mice were
prepared as previously described [9] and were stimulated with
different doses of rHMGB1 and pHMGB1. The corresponding
amount of LPS from E. coli was used for cell stimulation as a
control for rHMGB1. Cell culture supernatants were collected
after 24 hours and 48 hours for determination of the IL-6 level,
as previously described [9].
For the in vitro proliferation assay, splenocyte cultures were
prepared; the cells were then incubated for 72 hours in 96-
well plates with final concentrations of 0.05 μg/ml, 0.5 μg/ml,
and 5 μg/ml pHMGB1. Culture medium was used as a nega-
tive control, and concavalin A at a concentration of 2.5 μg/ml
as a positive control. The cultures were pulsed with 1 μCi triti-
ated thymidine 12 hours before harvesting, and the tritiated
thymidine uptake was counted in a beta counter. The prolifer-
ative response is expressed as the mean ± standard error of
the mean (median) counts per minute of triplicate samples
from five spleens in each group.
Statistical analysis
Nonparametric methods were used for statistical comparisons
since the data showed a non-normal distribution. Statistical
differences between independent groups were calculated
using the Mann–Whitney U test. P < 0.05 was considered
significant.
Results
Induction of arthritis by HMGB1 in TNFα-/- mice and in 
control mice
To assess the importance of the TNFα signalling pathway in
HMGB1-triggered arthritis, TNFα-/- mice and control TNFα+/+
mice were given a single intraarticular injection of 5 μg
pHMGB1 into a knee joint. This dose has been established in
previous experiments to induce arthritis [4]. Intraarticular injec-
tion of HMGB1 into healthy mouse joints resulted in an overall
frequency of 32% to 39% arthritic animals as assessed histo-
logically. No significant differences were found with respect to
the severity and incidence of arthritis between mice deficient
for TNFα (seven out of 18 mice with arthritis) in comparison
with control TNFα+/+ animals (six out of 19). The inflammation
was characterized by mild synovitis (Figure 1).Available online http://arthritis-research.com/content/10/3/R72
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Six mice in both groups received 5 μg rHMGB1 intraarticu-
larly, which is known to contain a higher concentration of LPS.
As a control, the contralateral knee joint of those mice was
injected with 10 ng LPS, a dose corresponding to the LPS
present in the rHMGB1 preparations used for injection. We
could not observe any significant differences regarding arthri-
tis severity in mice receiving rHMGB1 between mice with or
mice without the functional TNFα gene (Figure 1). Two mice
out of the six injected with 10 ng LPS displayed mild synovitis
in both groups irrespective of the presence or absence of the
TNFα gene. These results indicate that HMGB1 induces joint
inflammation in vivo independently of the TNFα pathway.
Cytokine response to HMGB1 in TNF-/- mice
We next examined whether TNFα deficiency affects a proin-
flammatory cytokine response to HMGB1 in vitro. Mouse
splenocytes from TNFα-/- mice and from control TNFα+/+ mice
were stimulated with 0.05 μg, 0.5 μg and 5 μg pHMGB1 for
24 hours and 48 hours, and the IL-6 production in cell culture
supernatants was determined. Stimulation with pHMGB1 did
not induce significant IL-6 release from TNFα-/- cells as com-
pared with TNFα+/+ splenocytes at any time point and irre-
spective of the pHMGB1 concentration used (Table 1).
In another experiment, spleen cells from TNF-/- mice and from
control mice were prepared and stimulated with 0.5 μg/ml and
5 μg/ml rHMGB1 for 24 hours and 48 hours. As a control, the
splenocytes were stimulated with 10 ng LPS, a dose corre-
sponding to that present in the highest HMGB1 preparations.
The results show that, upon stimulation with 0.5 μg/ml
rHMGB1, the TNFα+/+ cells released significantly more IL-6
than cells from the knockout mice after 24 hours (P < 0.05)
and 48 hours (P < 0.03) (Table 1). No significant differences
were detected, however, between spleen cells from TNFα+/+
mice versus TNFα-/- mice regarding IL-6 production upon stim-
Figure 1
Arthritis induction by high mobility group box chromosomal protein 1 in  TNFα-/- mice and controls Arthritis induction by high mobility group box chromosomal protein 1 in 
TNFα-/- mice and controls. Arthritis incidence (%) and arthritis severity 
scores (mean ± standard error of the mean) are shown in TNFα-/- mice 
(squares) and in control mice (circles) (n = 18 to 19 per group) follow-
ing a single intraarticular injection of 5 μg high mobility group box chro-
mosomal protein 1 (HMGB1). Empty squares/circles, individual mice (n 
= five to six per group) receiving recombinant HMGB1 containing a 
minimal amount of lipopolysaccharide (see Materials and methods); 
filled squares/circles, mice (n = 12 to 14 per group) receiving lipopoly-
saccharide-free HMGB1.
Table 1
Production of IL-6 following 24 hours and 48 hours of stimulation with different doses of purified recombinant endotoxin-free high 
mobility group box chromosomal protein 1 (pHMGB1) and mouse recombinant high mobility group box chromosomal protein 1 
(rHMGB1)
Time Mice IL-6 production (pg/ml) Lipopolysaccharidea
0 μg/ml HMGB1 0.05 μg/ml HMGB1 0.5 μg/ml HMGB1 5 μg/ml HMGB1
PHMGB1
24 hours TNFα-/- 17.0 ± 2.3 17.6 ± 2.2 17.8 ± 2.4 13.1 ± 4.6 2,460 ± 226
TNFα+/+ 16.2 ± 1.9 15.9 ± 2.0 16.8 ± 3.2 7.3 ± 3.1 6,905 ± 1,763
48 hours TNFα-/- 19.1 ± 3.0 20.1 ± 2.9 17.0 ± 1.6 26.3 ± 3.8
TNFα+/+ 19.8 ± 2.2 18.3 ± 2.2 14.2 ± 2.3 20.2 ± 3.2
RHMGB1
24 hours TNFα-/- 28 ± 16 304 ± 50* (314) 2,317 ± 264 (2,271) 146 ± 46* (130)
TNFα+/+ 68 ± 11 602 ± 112 (558) 3,046 ± 757 (2,504) 344 ± 63 (359)
48 hours TNFα-/- 213 ± 58 468 ± 56* (500) 2,541 ± 258 (2,588) 238 ± 79 (207)
TNFα+/+ 263 ± 33 1,133 ± 202 (1,062) 4,114 ± 941 (3,527) 438 ± 62 (408)
Data presented as the mean ± standard error of the mean of 10 mice per each group (pHMGB1), and the mean ± standard error of the mean 
(median) of four mice in each group (rHMGB1). HMGB1, high mobility group box chromosomal protein 1. apHMGB1, 5 μg/ml; rHMGB1, 10 ng/
ml. *P < 0.05 TNFα-/- mice versus control mice.Arthritis Research & Therapy    Vol 10 No 3    Pullerits et al.
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ulation with 5 μg/ml rHMGB1 after 24 hours and 48 hours. As
a control, stimulation with 10 ng/ml LPS (corresponding to the
amount found in 5 μg/ml rHMGB1) induced approximately
100 times less IL-6 than stimulation with 5 μg/ml rHMGB1 in
TNFα+/+ cultures as well as TNFα-/- splenocyte cultures after
24 hours and 48 hours (Table 1).
Proliferation
To assess the impact of HMGB1 on the reactivity of immuno-
competent cells in the presence or absence of the TNFα gene,
spleen cells from TNFα+/+ mice and from knockout mice were
stimulated with different concentrations of endotoxin-free
pHMGB1 and the proliferative response was scored after 72
hours. Upon stimulation with the highest HMGB1 dose (5 μg/
ml), TNFα+/+  mice had a significantly better proliferative
response than their knockout littermates (285 ± 51 (median
264) counts per minute versus 197 ± 15 (median 185) counts
per minute, respectively; P < 0.05), whereas no differences
were seen regarding proliferation at lower HMGB1 concentra-
tions (Figure 2). In addition, knockout mice had a threefold to
fourfold lower response to concavalin A, a compound known
to act on T lymphocytes, as compared with the TNFα+/+ mice
(3,700 ± 246 (median 3,668) counts per minute versus 7,423
± 1,043 (median 6,550) counts per minute, respectively; P =
0.009).
Discussion
In the present study we demonstrate that HMGB1-triggered
joint inflammation is not mediated via the TNF pathway since
the arthritis incidence and severity remained similar in mice
deficient for TNFα and in backcrossed C57Bl6 control
animals.
We have previously shown that the overall frequency and
severity of HMGB1-induced arthritis varies between different
mouse strains. In the case of C57Bl/6 mice, only 40% develop
arthritis – and the severity of inflammation in the joints also
proved to be significantly lower in comparison with other
mouse strains tested [4]. In the present study we observed
mild synovial inflammation in 32% to 39% of mice upon
intraarticular injection of HMGB1, which is in accordance with
our previous report [4].
In our in vitro study we observed no differences regarding IL-
6 production from splenocyte cultures between TNFα-/- mice
and TNFα+/+ mice in response to stimulation with either endo-
toxin-free or LPS-containing HMGB1. The latter LPS-contain-
ing HMGB1, however, induced a much higher IL-6 response
Figure 2
Impact of high mobility group box chromosomal protein 1 on reactivity in the presence/absence of TNFα Impact of high mobility group box chromosomal protein 1 on reactivity in the presence/absence of TNFα. Proliferative responses of splenocytes from 
TNFα+/+ mice and from TNFα-/- mice (n = five mice per group) incubated with different doses of (a) lipopolysaccharide-free purified recombinant 
endotoxin-free high mobility group box chromosomal protein 1 (pHMGB1) or (b) concavalin A (con A). Box plots, 25th and 75th percentiles; horizon-
tal solid lines, medians; horizontal hatched lines, means; vertical bars, 5th and 95th percentiles. Statistical differences were calculated using the 
Mann–Whitney U test. CPM, counts per minute.Available online http://arthritis-research.com/content/10/3/R72
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as compared with the endotoxin-free preparation. The higher
activity of the recombinant HMGB1 to induce IL-6 release can-
not be explained only by the endotoxin contamination since the
corresponding dose of LPS found in HMGB1 preparations
induced a 100-fold lower production of IL-6 than HMGB1. The
synergistic effect of LPS and HMGB1 mediated via Toll-like
receptor 4 could account for the increased production of
proinflammatory IL-6 release demonstrated in our study.
HMGB1 is a potent inducer of several proinflammatory
cytokines. One of these cytokines, IL-1, is considered a crucial
mediator in the pathogenesis of destructive arthritis along with
TNFα [7]. There is a great deal of crosstalk between IL-1 and
TNFα but their pathways differ nevertheless, and production of
IL-1 may occur independently of TNFα [10]. In our previous
study, we demonstrated that mice deficient for IL-1 receptor
did not develop arthritis upon intraarticular administration of
HMGB1 [4]. Furthermore, Park and colleagues reported in
their study that TNF-receptor associated factor 2 – which is
not associated with TLR/IL-1 receptor, but rather with TNF
receptors – did not appear to be involved in HMGB1 signal-
ling [11]. Sha and colleagues demonstrated recently that IL-1β
was bound to HMGB1 isolated from cells cultured with this
cytokine, and addition of anti-IL-1β antibodies or the IL-1
receptor antagonist to cell cultures blocked the proinflamma-
tory activity of HMGB1 [12], further suggesting that the proin-
flammatory action of HMBG1 is likely to be mediated by IL-1
activation.
Conclusion
Our results show that pathways other than TNFα are involved
in the initiation of joint inflammation in the case of HMGB1-
induced arthritis. Combined with our previous study [4], we
suggest that HMBG1-triggered arthritis is probably mediated
by IL-1 activation.
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